Literature DB >> 11190416

Differential pharmacokinetics of digoxin in elderly patients.

C G Hanratty1, P McGlinchey, G D Johnston, A P Passmore.   

Abstract

Digoxin remains one of the most commonly prescribed of all cardiac medications. The main indications for digoxin usage include atrial fibrillation and heart failure; both these conditions are more prevalent in older patients. Given the aging population and the increasing incidence of heart failure we would expect prescribing of digoxin to remain as frequent or to even increase in older patients. Older patients are also more likely to develop toxicity and diagnosis of digoxin toxicity can be difficult in this group. Numerous components contribute to the development of toxicity in older patients, ranging from aging-related changes in renal function or body mass to polypharmacy and possible interactions with digoxin. It is therefore important to understand how the pharmacokinetics of digoxin may be altered in the older population. Application of basic pharmacological principles may be helpful in anticipating these problems. This review describes the pharmacokinetics of digoxin, the changes in pharmacokinetics with increasing age and how concomitant disease states or drug interactions may affect the pharmacokinetics of digoxin. Greater knowledge about the causes and prevention of digoxin toxicity should further reduce the morbidity and mortality arising from digoxin toxicity, especially in the elderly population.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11190416     DOI: 10.2165/00002512-200017050-00003

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  86 in total

1.  Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers.

Authors:  M De Smet; D F Schoors; G De Meyer; R Verbesselt; M R Goldberg; V Fitzpatrick; G Somers
Journal:  Br J Clin Pharmacol       Date:  1995-12       Impact factor: 4.335

2.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

3.  Steady state serum concentrations of pravastatin and digoxin when given in combination.

Authors:  J Triscari; B N Swanson; D A Willard; A I Cohen; A Devault; H Y Pan
Journal:  Br J Clin Pharmacol       Date:  1993-09       Impact factor: 4.335

4.  Effect of furosemide on the renal excretion of digoxin.

Authors:  D D Brown; J C Dormois; G N Abraham; K Lewis; K Dixon
Journal:  Clin Pharmacol Ther       Date:  1976-10       Impact factor: 6.875

5.  Age-related digoxin-alprazolam interaction.

Authors:  H Guven; Y Tuncok; S Guneri; C Cavdar; J Fowler
Journal:  Clin Pharmacol Ther       Date:  1993-07       Impact factor: 6.875

6.  Enhanced cardiac effect of digoxin during quinidine treatment.

Authors:  E B Leahey; J A Reiffel; R H Heissenbuttel; R E Drusin; W P Lovejoy; J T Bigger
Journal:  Arch Intern Med       Date:  1979-05

7.  Interaction between quinidine and digoxin.

Authors:  E B Leahey; J A Reiffel; R E Drusin; R H Heissenbuttel; W P Lovejoy; J T Bigger
Journal:  JAMA       Date:  1978-08-11       Impact factor: 56.272

8.  Pharmacokinetic effects of fluvastatin in patients chronically receiving digoxin.

Authors:  W R Garnett; J Venitz; R C Wilkens; G Dimenna
Journal:  Am J Med       Date:  1994-06-06       Impact factor: 4.965

9.  The effect of quinidine and other oral antiarrhythmic drugs on serum digoxin. A prospective study.

Authors:  E B Leahey; J A Reiffel; E G Giardina; J T Bigger
Journal:  Ann Intern Med       Date:  1980-05       Impact factor: 25.391

10.  The MDR1 gene product, P-glycoprotein, mediates the transport of the cardiac glycoside, digoxin.

Authors:  I A de Lannoy; M Silverman
Journal:  Biochem Biophys Res Commun       Date:  1992-11-30       Impact factor: 3.575

View more
  23 in total

Review 1.  The influence of cardiovascular physiology on dose/pharmacokinetic and pharmacokinetic/pharmacodynamic relationships.

Authors:  Pietro Fagiolino; Rosa Eiraldi; Marta Vázquez
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

2.  Necessary cautions when considering digoxin in heart failure.

Authors:  George A Heckman; Robert S McKelvie
Journal:  CMAJ       Date:  2007-02-27       Impact factor: 8.262

3.  Impact of reduced P-glycoprotein function on digoxin concentrations in patients with dementia.

Authors:  Izna Ali; Daniel Guidone; Joseph A Nicolazzo; Kim L R Brouwer
Journal:  Br J Clin Pharmacol       Date:  2019-08-19       Impact factor: 4.335

Review 4.  The clinical implications of ageing for rational drug therapy.

Authors:  Shaojun Shi; Klaus Mörike; Ulrich Klotz
Journal:  Eur J Clin Pharmacol       Date:  2008-01-05       Impact factor: 2.953

Review 5.  Pharmacotherapy of heart failure in the elderly: adverse events.

Authors:  Michael W Rich
Journal:  Heart Fail Rev       Date:  2012-09       Impact factor: 4.214

6.  Population pharmacokinetic model of digoxin in older Chinese patients and its application in clinical practice.

Authors:  Xiao-dan Zhou; Yan Gao; Zheng Guan; Zhong-dong Li; Jun Li
Journal:  Acta Pharmacol Sin       Date:  2010-06       Impact factor: 6.150

7.  Risk of digoxin intoxication in heart failure patients exposed to digoxin-diuretic interactions: a population-based study.

Authors:  Meng-Ting Wang; Chen-Yi Su; Agnes L F Chan; Pei-Wen Lian; Hsin-Bang Leu; Yu-Juei Hsu
Journal:  Br J Clin Pharmacol       Date:  2010-08       Impact factor: 4.335

Review 8.  Atrial fibrillation in the elderly: facts and management.

Authors:  Guy Chatap; Karine Giraud; Jean-Pierre Vincent
Journal:  Drugs Aging       Date:  2002       Impact factor: 3.923

9.  Population Pharmacokinetic Studies of Digoxin in Adult Patients: A Systematic Review.

Authors:  Mariam Abdel Jalil; Noura Abdullah; Mervat Alsous; Khawla Abu-Hammour
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2021-05       Impact factor: 2.441

10.  Risk of digoxin intoxication caused by clarithromycin-digoxin interactions in heart failure patients: a population-based study.

Authors:  Agnes L F Chan; Meng-Ting Wang; Chen-Yi Su; Fu-Hsiung Tsai
Journal:  Eur J Clin Pharmacol       Date:  2009-12       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.